GFAP and Alzheimer disease: Despite previous reports of reactive astrocytes and microglia by 6–8 months in TgF344-AD rats via anti-GFAP or anti-Iba-1 IHC (Cohen et al., 2013; Rorabaugh et al., 2017), and although Disterhoft et al., add year has demonstrated increases in GFAP protein starting at 6–8 months assessed via mass spectroscopy in bulk CA1 homogenate (Bac et al., 2023), we observed no detectable difference in GFAP protein levels in DG measured in Western blot across genotype or treatment.